Kenvue Inc. (NYSE:KVUE) Shares Sold by Tradition Wealth Management LLC

Tradition Wealth Management LLC trimmed its stake in shares of Kenvue Inc. (NYSE:KVUE) by 14.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,830 shares of the company’s stock after selling 2,471 shares during the quarter. Tradition Wealth Management LLC’s holdings in Kenvue were worth $343,000 at the end of the most recent quarter.

Several other large investors also recently bought and sold shares of KVUE. Riverview Trust Co purchased a new position in shares of Kenvue in the 3rd quarter valued at about $30,000. Ashton Thomas Securities LLC purchased a new position in Kenvue in the third quarter worth approximately $35,000. Deseret Mutual Benefit Administrators grew its holdings in Kenvue by 49.7% during the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company’s stock worth $45,000 after acquiring an additional 651 shares in the last quarter. Studio Investment Management LLC increased its position in shares of Kenvue by 52.1% in the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company’s stock valued at $45,000 after purchasing an additional 845 shares during the last quarter. Finally, Brooklyn Investment Group acquired a new stake in shares of Kenvue in the 3rd quarter valued at $71,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Kenvue Stock Down 0.2 %

KVUE stock opened at $24.08 on Monday. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69. The company has a market cap of $46.17 billion, a price-to-earnings ratio of 43.78, a price-to-earnings-growth ratio of 2.19 and a beta of 1.36. The company has a fifty day moving average price of $22.94 and a 200 day moving average price of $20.99.

Kenvue (NYSE:KVUE) last announced its earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The business had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business’s revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.31 earnings per share. Sell-side analysts expect that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Wednesday, November 27th. Shareholders of record on Wednesday, November 13th were paid a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, November 13th. This represents a $0.82 annualized dividend and a dividend yield of 3.41%. Kenvue’s dividend payout ratio (DPR) is currently 149.09%.

Wall Street Analyst Weigh In

KVUE has been the topic of several recent analyst reports. UBS Group increased their target price on Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Jefferies Financial Group initiated coverage on Kenvue in a research report on Tuesday, September 24th. They set a “buy” rating and a $27.00 target price on the stock. Bank of America upped their price target on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a report on Tuesday, October 22nd. Deutsche Bank Aktiengesellschaft raised their price objective on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, Royal Bank of Canada cut shares of Kenvue from an “outperform” rating to a “sector perform” rating and set a $24.00 target price for the company. in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Kenvue currently has an average rating of “Hold” and a consensus target price of $22.64.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.